Drugs / Epsom salt
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT04708340 Comparator | Mar 2021 → Oct 2022 | COVID-19, acute respiratory distress syndrome | Reven Pharmaceuticals, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT06393608 Comparator | Jun 2024 → Dec 2025 overdue | — | Antoine Roger | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Epsom salt | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06393608 ↗ |
| Known as | magnesium sulfate heptahydrate | “Active drug comprised of: ascorbic acid, magnesium sulfate heptahydrate, cyanocobalamin, thiamine, riboflavin 5' phosphate, niacinamide, pyridoxine, calcium d-pantothenate, and...” NCT04708340 ↗ |
| Route | Topical | “topical application of compresses soaked in 25% magnesium sulfate” NCT06393608 ↗ |